Dornase - Latest Advances

Journal: Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies

Published: March 06, 2025

Inhalable micro/nanoparticles for pulmonary delivery of macromolecular therapeutics: A review.

Journal: Biomaterials

Published: February 27, 2025

Impact of Number of Pharmacies on Dornase Alfa Medication Possession Ratio in Children With Cystic Fibrosis.

Journal: Pediatric pulmonology

Published: February 13, 2025

Lung tissue-optimized gene editing in human cystic fibrosis models following topical application of lipid nanoparticles.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: February 07, 2025

Filters

The impact of dornase alfa on imaging features of bronchiectasis.

The impact of dornase alfa on imaging features of bronchiectasis.

Haemorrhagic Pericardial Effusion Following Intrapleural Fibrinolysis Therapy With Alteplase/Dornase Alfa for Complicated Parapneumonic Effusion: A Case Report.

Haemorrhagic Pericardial Effusion Following Intrapleural Fibrinolysis Therapy With Alteplase/Dornase Alfa for Complicated Parapneumonic Effusion: A Case Report.

Progressive Pulmonary Lesion due to Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction: A Case Study From Japan.

Progressive Pulmonary Lesion due to Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction: A Case Study From Japan.

A severe early presentation of cystic fibrosis in an infant with a homozygous c.1375_1383del CFTR variant- a case report.

A severe early presentation of cystic fibrosis in an infant with a homozygous c.1375_1383del CFTR variant- a case report.

Preclinical Safety.

Preclinical Safety.

Persistent Atelectasis Prevalence and Incidence in Pediatric Critical Care.

Persistent Atelectasis Prevalence and Incidence in Pediatric Critical Care.

The Efficacy of Dornase Alpha (Polmozyme) in Resolving Persistent Atelectasis in Pediatric Critical Care.

The Efficacy of Dornase Alpha (Polmozyme) in Resolving Persistent Atelectasis in Pediatric Critical Care.

Real-world outcomes after initiation of Elexacaftor/tezacaftor/ivacaftor in an adolescent cohort with cystic fibrosis.

Real-world outcomes after initiation of Elexacaftor/tezacaftor/ivacaftor in an adolescent cohort with cystic fibrosis.

Patterns of Use of β-2 Agonists, Steroids, and Mucoactive Medications to Treat Bronchiolitis in the PICU: U.S. Pediatric Health Information System 2009-2022 Database Study.

Patterns of Use of β-2 Agonists, Steroids, and Mucoactive Medications to Treat Bronchiolitis in the PICU: U.S. Pediatric Health Information System 2009-2022 Database Study.

Inhalable micro/nanoparticles for pulmonary delivery of macromolecular therapeutics: A review.

Inhalable micro/nanoparticles for pulmonary delivery of macromolecular therapeutics: A review.

Impact of Number of Pharmacies on Dornase Alfa Medication Possession Ratio in Children With Cystic Fibrosis.

Impact of Number of Pharmacies on Dornase Alfa Medication Possession Ratio in Children With Cystic Fibrosis.

Lung tissue-optimized gene editing in human cystic fibrosis models following topical application of lipid nanoparticles.

Lung tissue-optimized gene editing in human cystic fibrosis models following topical application of lipid nanoparticles.